basal ganglia diseases/headache

Lyen an sove nan clipboard la

Chwazi kalite sòt

11 rezilta yo

Migraine headache in patients with Sydenham's chorea.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

We compared the frequency of migraine among Sydenham's chorea (SC) patients, rheumatic fever (RF) patients without neurological symptoms and matched controls. Migraine was more frequent in SC patients (12/55, 21.8%) than in controls (9/110, 8.1%) and as common as in the RF group (10/55, 18.2%). Our

Temporal arteritis presenting as an extrapyramidal disorder.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

A case of temporal arteritis presenting with extrapyramidal symptoms (tremor, rigidity and extrapyramidal hypertonus) unresponsive to conventional treatment is here described. The onset of headache and laboratory abnormalities suggestive of temporal arteritis prompted a temporal artery biopsy which

The prospective natural history of cerebral venous malformations.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE A 10-year prospective clinical and magnetic resonance imaging study was undertaken to determine the natural history of venous malformations. We assessed the hemorrhage rate and morbidity associated with venous malformations of the brain. METHODS From 1986 to 1996, 80 patients with venous

Initial experience with technetium-99m HM-PAO brain SPECT.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Technetium-99m hexamethylpropyleneamineoxime ([99mTc]HM-PAO) brain single photon emission computed tomography (SPECT) was performed with a dual head rotating scintillation camera. Normal tracer distribution and side/side differences of counting rates were obtained in 11 healthy volunteers. Almost

An open-label tolerability study of BL-1020 antipsychotic: a novel gamma aminobutyric acid ester of perphenazine.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND BL-1020, a novel gamma aminobutyric acid (GABA) ester of perphenazine, is a new oral antipsychotic with a strong affinity for dopamine and serotonin receptors. Unlike first- and second-generation antipsychotics, it has agonist activity at GABA(A). OBJECTIVE This is the first study to

Going high with preexisting neurological conditions.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

This review presents the potential impact of high altitude exposure on preexisting neurological conditions in patients usually living at low altitude. The neurological conditions include permanent and transient ischemia of the brain, occlusive cerebral artery disease, cerebral venous thrombosis,

Chapter 2: mesopotamia.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

No treatise of ancient Mesopotamian clinical neurology has yet been written, although much groundbreaking work on medical or medically-related texts from this area (modern Iraq) has been performed in recent years. All through Mesopotamian civilization (c. 3000-100 BC), literary and erudite

Pharmacological prevention of migraine: to be considered case by case.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

(1) Migraines are characterized by recurrent headaches generally lasting between 4 and 72 hours and disappearing without complication. They can be incapacitating, owing to their frequency and/or intensity. (2) Many drugs have been used to prevent migraines. One of the most common outcome measures

The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Schizophrenia is a chronic and debilitating neuropsychiatric disorder that often requires long-term pharmacotherapy to manage symptoms and prevent relapse. Cariprazine is a potent dopamine D3 and D2 receptor partial agonist that is FDA-approved in the US for the treatment of schizophrenia and manic

The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE Cariprazine, an orally active and potent dopamine D3 and D2 receptor partial agonist with preferential binding to D3 receptors, is being developed for the treatment of schizophrenia and bipolar mania. This Phase II trial evaluated the efficacy, safety, and tolerability of cariprazine

Aripiprazole for the treatment of pediatric bipolar I disorder: a 30-week, randomized, placebo-controlled study.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE To evaluate the long-term efficacy, safety, and tolerability of aripiprazole in pediatric subjects with bipolar I disorder. METHODS A randomized, double-blind, 30-week, placebo-controlled study of aripiprazole (10 or 30 mg/day) in youths (10-17 years) with bipolar I disorder (manic or

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye